CeleCor Submits NDA for Zalunfiban After Positive CeleBrate Trial Results

CeleCor Therapeutics has submitted the final section of its rolling New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for zalunfiban (Disaggpro™), an investigational subcutaneous antiplatelet therapy for patients with ST-segment elevation myocardial infarction (STEMI). The submission marks a major regulatory milestone following positive Phase 3 results from the pivotal CeleBrate trial, which demonstrated clinically meaningful improvements in coronary reperfusion and cardiovascular outcomes.

Zalunfiban previously received FDA Fast Track designation and Rolling Review, allowing regulators to evaluate portions of the application before completion and potentially shortening the overall review timeline.

Zalunfiban Targets Early Platelet Blockade in STEMI

STEMI is the most severe form of heart attack, occurring when a coronary artery becomes completely blocked, rapidly depriving heart muscle of oxygen. Delays in restoring blood flow increase the risk of irreversible myocardial damage, heart failure, and death.

Zalunfiban is a next-generation, small-molecule glycoprotein IIb/IIIa (GPIIb/IIIa) receptor inhibitor developed for rapid administration at the first point of medical contact, including in ambulances, patients’ homes, or emergency departments. Administered as a single subcutaneous injection, the drug reaches maximal platelet inhibition within approximately 15 minutes, with antiplatelet activity declining after about two hours.

Phase 3 CeleBrate Trial Met Primary Efficacy and Safety Endpoints

The pivotal CeleBrate Phase 3 study (NCT04825743) enrolled 2,467 STEMI patients across 45 centers in the United States, Canada, Mexico, and Europe. The randomized, placebo-controlled, blinded international trial evaluated whether pre-hospital administration of zalunfiban could improve outcomes before patients underwent primary percutaneous coronary intervention (PCI).

Treatment with zalunfiban increased coronary blood flow before PCI and reduced the risk of experiencing a larger myocardial infarction or one complicated by death, stroke, reinfarction, stent thrombosis, or heart failure by approximately 21% compared with placebo.

The study met both its primary efficacy and primary safety endpoints. Zalunfiban did not significantly increase major bleeding, while minor and moderate bleeding events occurred more frequently but were not associated with increased mortality or adverse long-term outcomes.

Investigators also reported that early treatment helped preserve myocardial perfusion until patients reached the cardiac catheterization laboratory, supporting rapid intervention before definitive revascularization.

Early Treatment Could Improve Outcomes in Patients Facing Treatment Delays

The benefit of early platelet inhibition may be particularly important for patients living in rural regions or those requiring transfer to PCI-capable hospitals, where treatment delays remain common. Faster restoration of coronary blood flow could reduce irreversible myocardial injury and lower the long-term risk of heart failure.

CeleBrate principal investigator Prof. Arnoud W.J. van ‘t Hof said the findings suggest pre-hospital administration of zalunfiban has the potential to change how STEMI patients are treated by improving coronary reperfusion before catheterization.

Dr. C. Michael Gibson, Professor of Medicine at Harvard Medical School, added that, if approved, the therapy could allow emergency responders to begin effective treatment immediately after diagnosis, reducing severe heart damage before hospital intervention.

FDA Review Begins as Commercial Preparation Advances

Completion of the NDA submission initiates the FDA review process for zalunfiban. Alongside the regulatory filing, CeleCor appointed Michael Moye as Chief Commercial Officer to lead commercialization planning should the therapy receive approval.

If approved, zalunfiban could become one of the first rapidly administered subcutaneous GPIIb/IIIa inhibitors specifically developed for pre-hospital STEMI treatment, potentially expanding access to early antiplatelet therapy and improving outcomes for patients experiencing the most severe form of acute myocardial infarction.

What This Means for Patients

For people experiencing a severe heart attack (STEMI), every minute without blood flow causes permanent damage to the heart muscle. If approved, zalunfiban could allow emergency medical teams to start treatment immediately at the first point of medical contact, even before the patient reaches the hospital. Administered as a small subcutaneous injection, the drug reaches its maximum antiplatelet effect within 15 minutes, helping restore blood flow quickly while patients are being transported for definitive treatment. Its effect wears off after about two hours and returns to baseline within four hours, supporting rapid treatment without prolonged platelet inhibition. This early intervention may reduce heart damage, lower the risk of complications such as heart failure, stroke, or death, and improve recovery, particularly for patients who face delays in reaching a PCI-capable hospital.

Reference

CeleCor completes submission of FDA New Drug Application for investigational heart-attack drug – CeleCor Therapeutics

Rapid zalunfiban treatment at 1st point of medical contact lowered risk of more severe heart damage in combination with other serious heart-attack complications – CeleCor Therapeutics